Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Countries around the world are trying to tackle the escalating H1N1 (swine flu) pandemic in different ways. Advice from all authorities, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), remains the same: good hand hygiene, particularly in public places. Despite this, there are still too few people who know how to wash and dry their hands in the most hygienic way.
Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today reported that the company’s proprietary influenza vaccine triggered a robust immune response and provided protection against the H1N1 strain of influenza.
"The Dr. Oz Show," a high octane, multi-topic hour-long series hosted by trusted health expert, best-selling author, and world-renowned cardiac surgeon Dr. Mehmet Oz, premieres in syndication today (check local listings). Episodes airing during its premiere week feature two of the recently announced "Core Team Oz" guest contributors, fashion and style expert Tim Gunn ("Project Runway") and fitness specialist Bob Harper ("The Biggest Loser"). Also debuting this week as a member of Core Team Oz is "America's vet," Dr. Marty Becker, the popular author and regular veterinary contributor on ABC-TV's "Good Morning America."
Carnegie Mellon University, the University of Pittsburgh and UPMC (University of Pittsburgh Medical Center) have driven a dramatic shift in the Pittsburgh economy during the last four decades, transforming the city from a manufacturing town to an international knowledge-based center for research, education and medicine.
Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.
NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA.
With the early onset of flu season coinciding with the start of school this year, concern about the flu, and in particular the H1N1 strain of the flu, is growing among parents. Experts from The Children’s Hospital in Denver, Colo., can offer a pediatric perspective on all types of flu, including H1N1, also known as swine flu.
Indiana State University's exposure this week to the H1N1 virus has one of the school's environmental health sciences professors using the campus as her classroom.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, also is conducting clinical trials of 2009 H1N1 influenza vaccines, produced by Sanofi Pasteur and CSL Limited. The NIAID trials are testing two different dosages (15 micrograms versus 30 micrograms) and evaluating the immune response to one and two doses of these vaccines.
From Sunday, September 13 through Friday, September 18, 2009, health care professionals from across Prince Edward Island, will gather together to discuss best practices and strategies for managing emergency situations.
The results of clinical trials have shown one dose of the H1N1 (swine) flu vaccine is enough to offer adults protection against the virus, U.S. and Australian researchers said Thursday, the Associated Press reports (Neergaard, 9/11).
The American Lung Association is making it easier for people to get their seasonal flu vaccine this year with the availability of its 2009-2010 Flu Clinic Locator. The largest online directory of public seasonal influenza vaccination clinics is now available at www.flucliniclocator.org.
BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced today that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia, demonstrated that Ygiene® antimicrobial diluted 1 to 10 with water can totally eradicated the H1N1 Swine Flu virus in 59 seconds on an unclean, soiled surface.
A recent research study has given new scientific evidence to the long-held empirical belief that elderberries possess antiviral activities. The research involved a specific, reproducible elderberry extract developed by HerbalScience Group LLC, and succeeded in identifying key chemical components of the extract that inhibited in vitro infection and were shown to bind directly to Human Influenza A (H1N1) virus particles. The binding blocked the ability of the viruses to enter host cells, and thereby effectively preventing H1N1 infection in vitro.
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today that it currently anticipates its highest quarterly revenue and operating income in its history, driven by global shipments of its QuickVue® Influenza A+B tests in the third quarter of 2009.
A doctor who developed Guillain-Barr- syndrome will consider having the swine flu jab when she returns to work this autumn, despite claims that the vaccine is linked to an increased risk of the disease. Laura Claire Price, a specialist in respiratory and intensive care medicine, examines the reasons why the vaccine might cause the syndrome, reviews the current evidence, and concludes that she will consider having the jab when it becomes available.
Conflicting guidance on the depth and breadth of the H1N1 virus - the upcoming revisit of swine flu - has combined with other factors to result in dangerously low preparedness plans within the private sector.
As public health experts warn of potential widespread outbreaks of H1N1 flu this school year, a new study from North Carolina State University shows that students do not comply with basic preventative measures as much as they think do. In other words, the kids aren't washing their hands.
Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.